| 29.21 -2.13 (-6.8%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 44.94  |
1-year : | 51.71 |
| Resists | First : | 38.48 |
Second : | 44.27 |
| Pivot price | 33.83 |
|||
| Supports | First : | 29.1 |
Second : | 24.21 |
| MAs | MA(5) : | 32.15 |
MA(20) : | 35.71 |
| MA(100) : | 33.84  |
MA(250) : | 25.34 |
|
| MACD | MACD : | -2.2 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 7.7 |
D(3) : | 12.6 |
| RSI | RSI(14): 24.3 |
|||
| 52-week | High : | 44.27 | Low : | 14.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CSTL ] has closed above bottom band by 11.0%. Bollinger Bands are 76.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.64 - 31.82 | 31.82 - 31.96 |
| Low: | 28.7 - 28.91 | 28.91 - 29.08 |
| Close: | 28.9 - 29.21 | 29.21 - 29.47 |
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Thu, 19 Feb 2026
Prospective Validation Study in JAAD Demonstrates Castle - GlobeNewswire
Thu, 19 Feb 2026
New skin test steers severe eczema patients to faster JAK drug relief - Stock Titan
Thu, 19 Feb 2026
Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7% - Should You Sell? - MarketBeat
Thu, 19 Feb 2026
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Thu, 19 Feb 2026
Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on Thursday - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 29 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 90.5 (%) |
| Shares Short | 1,530 (K) |
| Shares Short P.Month | 1,720 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.02 |
| Profit Margin | -3.6 % |
| Operating Margin | -8.2 % |
| Return on Assets (ttm) | -1.8 % |
| Return on Equity (ttm) | -2.7 % |
| Qtrly Rev. Growth | -3.3 % |
| Gross Profit (p.s.) | 9.4 |
| Sales Per Share | 11.76 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 62 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | -66.39 |
| PEG Ratio | 0 |
| Price to Book value | 1.82 |
| Price to Sales | 2.48 |
| Price to Cash Flow | 13.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|